The role of PARP inhibitor target engagement in breast cancer
The role of PARP inhibitor target engagement in breast cancer
批准号:
9113529
负责人:
John Dubach
金额:
$17.91万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-08-01 至 2017-07-31
关键词:
Antineoplastic AgentsAreaBindingBiologicalBiologyBreast Cancer CellBreast Cancer ModelBreast Cancer TreatmentCell Culture TechniquesCellsClinicalClinical TrialsComplexDNA Double Strand BreakDataDevelopmentDoctor of PhilosophyDrug TargetingFailureFluorescence AnisotropyFluorescence PolarizationGeneral HospitalsGoalsHealthHeterogeneityHigh PrevalenceImageImaging TechniquesIn VitroLabelLifeLightMalignant NeoplasmsMassachusettsMeasurementMeasuresMentorsMentorshipMethodsMicroscopyModelingMusMutateMutationOutcomes ResearchPathway interactionsPharmaceutical PreparationsPhasePolarization MicroscopyPoly(ADP-ribose) PolymerasesProteinsResearch PersonnelResolutionRoleSystems BiologyTechniquesTestingTherapeuticTreatment FailureWorkanalogbasebiological systemscancer cellcancer therapycellular targetingclinically relevantdrug distributiondrug mechanismexperiencefluorescence imagingimaging systemin vivoin vivo Modelinhibitor/antagonistinsightintravital fluorescence microscopymalignant breast neoplasmmedical schoolsmouse modelmutantnovelresearch studyresponsesensorsuccesstargeted imagingtemporal measurementtreatment responsetriple-negative invasive breast carcinomatumor
中文摘要
描述(由申请人提供):这项提案的广泛目标是开发新的成像方法来了解体内药物活性的复杂生物学。具体来说,我会
开发和优化一种荧光偏振显微镜方法,以在小鼠肿瘤模型中以细胞分辨率成像癌症药物的靶标结合。这项名为竞争多光子荧光各向异性显微镜(CompMFAM)的技术能够通过与同一靶标的荧光标记药物竞争来成像未标记的药物靶标。当一种药物被证明无效时,通过测量目标参与度可以洞察治疗失败的机制。这些数据可以用来确定失败是由于药物分配效率低下还是靶点无法影响细胞。候选人J.Matt Dubach博士在为难以测量的目标进行荧光成像的新型传感器开发方面拥有丰富的经验。候选人的长期目标是开发新的成像方法,以便在生物系统的细胞水平上更好地了解癌症。这项拟议的工作将在马萨诸塞州总医院和哈佛医学院的系统生物学中心进行,由医学博士拉尔夫·韦斯莱德和博士蒂姆·米奇森指导。指导团队将在独立道路的指导阶段帮助候选人的发展,并帮助候选人转变为独立研究人员。这项建议的具体目标集中在两个领域:成像系统的技术开发;以及通过小鼠模型衡量PARP靶标参与在乳腺癌治疗中的作用的生物学应用。目前有几种前景看好的PARP抑制剂正在对各种癌症进行临床试验。很大程度上是因为
由于BRCA突变在乳腺癌中的高发生率,PARP抑制剂目前正被探索为三阴性乳腺癌的单一药物治疗。初步的可行性实验表明,这是一种定量测量体内药物靶向结合的有效方法。该提案有两个具体目标:1)验证CompMFAM技术以测量细胞水平的靶参与;2)确定靶参与如何管理成功的PARP抑制剂治疗。目标1将在指导小组的指导下完成,而目标2将作为独立调查员执行。这一建议的成功完成将使人们深入了解PARP靶标参与如何在成功和不成功的治疗中管理细胞反应,同时提供一种普遍的方法来研究几乎任何一种抑制剂药物类别的靶标参与。
英文摘要
DESCRIPTION (provided by applicant): The broad goal of this proposal is to develop new imaging approaches to understand the complex biology of drug activity in vivo. Specifically, I will
develop and optimize a fluorescence polarization microscopy approach to image target engagement of cancer drugs at cellular resolution in mouse tumor models. This technique, entitled competition multiphoton fluorescence anisotropy microscopy (compMFAM), enables imaging of unlabeled drug target engagement through competition with fluorescently labeled drug of the same target. Measuring target engagement provides insight into the mechanism of treatment failure when a drug proves ineffective. These data can be used to determine if failure arises from inefficient drug distribution or inability of the target to effect the cell. The candidte, J. Matt Dubach, PhD, has extensive experience in novel sensor development for fluorescent imaging of difficult to measure targets. The long term goal of the candidate is to develop novel imaging approaches to better understand cancer at the cellular level in biological systems. The proposed work will be conducted at the Center for Systems Biology at Massachusetts General Hospital and Harvard Medical School under the mentorship of Ralph Weissleder, MD, PhD and Tim Mitchison, PhD. The mentorship team will assist in the candidate's development during the mentored phase of the pathway to independence and help the candidate transition into an independent researcher. The specific aims of this proposal focus on two areas: technological development of the imaging system; and biological applications to measure the role of PARP target engagement in treatment of breast cancer through mouse models. There are several promising PARP inhibitors currently in clinical trials for a variety of cancers. Largely due to the
high prevalence of BRCA mutations in breast cancer, PARP inhibitors are currently be explored as single agent treatment in triple negative breast cancer. Preliminary feasibility experiments demonstrate that this is a valid approach to quantitatively measure target engagement of drug in vivo. There are two specific aims in this proposal: 1) Validate compMFAM technique to measure cellular level target engagement; and 2) Determine how target engagement governs successful PARP inhibitor treatment. Aim 1 will be accomplished under the mentorship team, while Aim 2 will be performed as an independent investigator. Successful completion of this proposal would provide insight into how PARP target engagement governs cellular response in successful and unsuccessful treatment while providing a generalizable approach to study target engagement of nearly any inhibitor drug class.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Optimizing PARP inhibitor therapy through novel approaches to resolve the molecular mechanisms of response
-
批准号:10670095
-
项目类别:
-
资助金额:$37.49万
-
财政年份:2019
-
负责人:John Dubach
-
依托单位:
Optimizing PARP inhibitor therapy through novel approaches to resolve the molecular mechanisms of response
-
批准号:10449322
-
项目类别:
-
资助金额:$38.26万
-
财政年份:2019
-
负责人:John Dubach
-
依托单位:
Optimizing PARP inhibitor therapy through novel approaches to resolve the molecular mechanisms of response
-
批准号:10212344
-
项目类别:
-
资助金额:$38.26万
-
财政年份:2019
-
负责人:John Dubach
-
依托单位:
The role of PARP inhibitor target engagement in breast cancer
-
批准号:9752234
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2017
-
负责人:John Dubach
-
依托单位:
The role of PARP inhibitor target engagement in breast cancer
-
批准号:9513108
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2017
-
负责人:John Dubach
-
依托单位:
The role of PARP inhibitor target engagement in breast cancer
-
批准号:8956858
-
项目类别:
-
资助金额:$17.91万
-
财政年份:2015
-
负责人:John Dubach
-
依托单位:
国内基金
海外基金
层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
-
批准号:2021JJ40433
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2021
-
负责人:孙磊
-
依托单位:
寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
-
批准号:32001603
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:段真珍
-
依托单位:
AREA国际经济模型的移植.改进和应用
-
批准号:18870435
-
项目类别:面上项目
-
资助金额:2.0万元
-
批准年份:1988
-
负责人:史树中
-
依托单位: